GlycoMark (1,5-AG): What Your Number Changes About Your Treatment

What GlycoMark (1,5-AG) Actually Measures

GlycoMark gives your clinician a two-week glucose "replay" that A1C cannot provide. The test measures 1,5-anhydroglucitol, a naturally occurring polyol found in food that circulates at a near-steady concentration in healthy, euglycemic people. When blood glucose rises above roughly 180 mg/dL, glucose spills into urine and competitively blocks renal reabsorption of 1,5-AG, flushing it out. The result: serum 1,5-AG falls rapidly after even a single postprandial spike.

Why This Complements A1C

A1C reflects average glucose over 90 days. That averaging effect can hide dangerous daily swings. A woman with an A1C of 6.8% who spikes to 240 mg/dL after every meal and then corrects quickly looks identical to a woman with steady, flat glucose. GlycoMark separates those two pictures. The FLAT-SUGAR study showed that 1,5-AG detected postprandial hyperglycemia with a sensitivity that A1C could not match in patients with near-normal glycated hemoglobin, making it especially useful when you feel like "something is off" but your A1C looks acceptable.

How Fast Does It Change?

The half-life of 1,5-AG in serum is short. Values can shift meaningfully within four to eight days of improved glycemic control, compared to the three-month lag of A1C. That speed makes GlycoMark practical for gauging whether a new medication or meal-timing change is actually reducing your glucose excursions, not just your fasting numbers.

Normal GlycoMark (1,5-AG) Range

For non-pregnant adult women, the reference range used by the GlycoMark assay (Glycosyns/Japan Institute for the Control of Aging) and reported in clinical validation studies is 10.7 to 32.0 mcg/mL. Results below 10 mcg/mL suggest frequent postprandial excursions above 180 mg/dL. Results below 6 mcg/mL indicate very poorly controlled postprandial glucose, often seen in overt type 2 diabetes with recurrent spikes.

Interpreting the Number by Glucose Context

| 1,5-AG (mcg/mL) | Postprandial glucose picture | |---|---| | <6 | Frequent, large excursions; glucose commonly exceeds 200 mg/dL | | 6-10 | Moderate excursions above 180 mg/dL most days | | 10-14 | Borderline; some postprandial spikes likely | | 14-32 | Within reference range; excursions above 180 mg/dL are rare | | >32 | Rare; may reflect very low carbohydrate intake |

These thresholds align with data from the Atherosclerosis Risk in Communities (ARIC) cohort, which linked 1,5-AG levels below 10 mcg/mL to significantly higher cardiovascular event rates independent of A1C.

Sex-Specific Reference Considerations

Men and women share the same reference interval in most validated assays, but lean body mass, renal tubular function, and dietary carbohydrate intake all influence baseline 1,5-AG and all differ systematically by sex. Women also have lower average glomerular filtration rates when adjusted for body surface area. No major guideline has yet issued a sex-stratified 1,5-AG reference range, which is an evidence gap worth knowing. What that means practically: a woman on the lower end of "normal" who also has PCOS or perimenopausal insulin resistance deserves closer clinical scrutiny even if her number clears the 10.7 cutoff.

What a Low GlycoMark Means for Your Treatment

A low 1,5-AG is not just a number to discuss at your next appointment. It changes what your clinician should prescribe. Here is how that plays out across the most common clinical scenarios.

Scenario 1: Low 1,5-AG with Near-Normal A1C

This pattern is the core clinical use case. If your A1C is 6.4% but your 1,5-AG is 8 mcg/mL, you are spiking high after meals more often than your A1C suggests. The American Diabetes Association Standards of Care acknowledge 1,5-AG as a useful complementary marker for capturing glycemic variability, particularly in people whose A1C may be misleading.

Treatment implications:

• A GLP-1 receptor agonist (semaglutide, liraglutide) or GIP/GLP-1 co-agonist (tirzepatide) may be preferred over metformin alone, because these agents specifically blunt postprandial excursions via glucose-dependent insulin secretion and delayed gastric emptying.
• A short-acting mealtime insulin or a rapid-acting analogue added to basal insulin becomes more defensible than simply titrating basal alone.
• Dietary coaching shifts from "reduce total carbohydrates" to "target postprandial spikes specifically," which is a different conversation.

Scenario 2: Low 1,5-AG with Elevated A1C

Here the two markers agree. Glucose control is broadly poor, and the 1,5-AG confirms that postprandial excursions are a major contributor. Intensification is clearly indicated. Your clinician will want to know whether fasting glucose or postprandial glucose is the larger driver, because that changes the medication class. Low 1,5-AG points toward postprandial excess, which responds well to alpha-glucosidase inhibitors (acarbose), GLP-1 agonists, or rapid-acting insulin at meals.

Scenario 3: Normal 1,5-AG with Elevated A1C

This pattern suggests that fasting hyperglycemia, not postprandial spikes, is the dominant problem. A long-acting basal insulin or a drug targeting hepatic glucose output (metformin) may be the priority. The normal 1,5-AG tells you the postprandial window is relatively controlled, so adding a drug specifically aimed at after-meal glucose would probably not move the needle much.

Scenario 4: Borderline 1,5-AG in a Woman Watching Her Weight

Women managing obesity-related insulin resistance frequently land in the 10-14 mcg/mL zone. For a woman on a GLP-1 agonist for weight, a rising 1,5-AG over successive draws is one of the most practical early signals that the medication is improving her postprandial physiology, even before A1C shifts meaningfully. Tracking 1,5-AG every four to eight weeks during titration gives faster feedback than waiting three months for an A1C.

How 1,5-AG Behaves Across Female Life Stages

Reproductive Years and PCOS

Women with polycystic ovary syndrome carry a threefold higher lifetime risk of type 2 diabetes compared to age-matched controls, driven partly by chronic postprandial hyperinsulinemia and insulin resistance. Yet many women with PCOS have A1C values in the prediabetes range or even low-normal, because their compensatory hyperinsulinemia keeps average glucose down while postprandial spikes still occur. GlycoMark can expose that gap.

If you have PCOS and your clinician is considering whether to add or intensify inositol supplementation, metformin, or a GLP-1 agonist, a low 1,5-AG alongside a normal-range A1C provides objective evidence that postprandial dysregulation is present and treatment-worthy.

Perimenopause and Menopause

Estrogen loss accelerates insulin resistance. In the Study of Women's Health Across the Nation (SWAN), progression from prediabetes to type 2 diabetes was faster in the menopause transition than in the years before or after. Many perimenopausal women describe eating the same food as always but gaining weight around the abdomen and feeling their blood sugar is "different." GlycoMark can objectify that feeling. A drop in 1,5-AG during the menopause transition, in a woman whose A1C is still technically normal, is clinically meaningful and may warrant earlier dietary or pharmacologic intervention than guidelines based solely on A1C would suggest.

Menopausal hormone therapy (MHT) modestly improves insulin sensitivity. The Women's Health Initiative and several smaller randomized trials found that oral and transdermal estrogen reduced fasting glucose and HOMA-IR in postmenopausal women. If you are on MHT, monitoring 1,5-AG before and after initiation can give a two-week snapshot of whether your postprandial glucose exposure is shifting.

Trying to Conceive

Preconception glycemic optimization reduces the risk of neural tube defects, miscarriage, and large-for-gestational-age birth. For a woman with type 2 diabetes or prediabetes planning pregnancy, a 1,5-AG trending upward toward normal (above 14 mcg/mL) in the weeks before conception attempts provides real-time confirmation that postprandial control is improving. This is faster feedback than waiting for A1C reassessment. The ACOG Practice Bulletin on pregestational diabetes recommends achieving near-normal glycemia before conception, and 1,5-AG is a practical tool for monitoring that goal in the short term.

Pregnancy and Lactation: Critical Limitations

1,5-AG is not validated for use during pregnancy and should not be used to monitor gestational diabetes or overall glycemic control in pregnant women.

Why: During normal pregnancy, renal glucose threshold drops and glycosuria increases even without hyperglycemia. This physiologic glucosuria causes 1,5-AG to fall independent of actual blood glucose levels. Studies confirm that 1,5-AG concentrations decline progressively across all trimesters in healthy pregnant women, making low values uninterpretable as a sign of glycemic deterioration.

Pregnancy monitoring tools: The standard remains the 75g oral glucose tolerance test for gestational diabetes diagnosis (ACOG/ADA guidelines) and continuous glucose monitoring or self-monitored blood glucose for ongoing management.

Postpartum: After delivery, glycosuria resolves within days. Once urine glucose excretion normalizes, 1,5-AG can theoretically resume reflecting postprandial glucose. No specific guideline currently specifies a validated timeline for resuming 1,5-AG testing postpartum; a conservative approach is to wait six to eight weeks after delivery and confirm with concurrent A1C. During lactation, carbohydrate metabolism is altered by prolactin, which has insulin-sensitizing effects in some women and may affect baseline 1,5-AG modestly. Again, data in lactating women are thin. Clinical decisions postpartum should prioritize A1C and continuous glucose monitoring data.

Drugs That Interfere with Your GlycoMark Result

This is one of the most consequential clinical pitfalls around this test, and your ordering clinician must know your medication list before interpreting the result.

SGLT2 Inhibitors: Major False Lowering

SGLT2 inhibitors (empagliflozin 10-25 mg, dapagliflozin 5-10 mg, canagliflozin 100-300 mg) work by blocking renal glucose reabsorption, which causes persistent glucosuria regardless of serum glucose level. That chronic urinary glucose loss depletes circulating 1,5-AG by exactly the same mechanism as hyperglycemia. Published pharmacology and clinical observations confirm that SGLT2 inhibitors cause profound, artifactual reductions in 1,5-AG that cannot be distinguished from true postprandial hyperglycemia. A woman on empagliflozin will have a falsely low 1,5-AG even if her postprandial glucose is perfectly controlled.

What this means for your care: If you take any SGLT2 inhibitor, GlycoMark results are uninterpretable. Do not stop the medication for testing; instead, use continuous glucose monitoring or structured postprandial self-monitoring to assess after-meal glucose.

Other Medications with Moderate Interference

• Chronic high-dose aspirin may affect renal tubular handling of 1,5-AG, though the magnitude is small and rarely clinically significant.
• Severe renal impairment (eGFR <30 mL/min/1.73m²): reduced renal excretion of glucose means 1,5-AG stays falsely elevated even during glucose excursions. Results are unreliable in stage 4-5 CKD.

Dietary Effects

Very-low-carbohydrate diets reduce dietary 1,5-AG intake (it is found in grains, legumes, and rice) and can lower serum levels modestly without any change in glycemic control. Women on strict ketogenic diets may see 1,5-AG at the low end of reference range, which could be misread as postprandial dysregulation. Context matters.

How to Raise a Low GlycoMark: The Treatment Targets

Raising your 1,5-AG is a byproduct of reducing postprandial glucose excursions above 180 mg/dL. Here are the strategies that have documented effects on 1,5-AG, with evidence.

Diet: Postprandial-First Approach

Reducing the glycemic load of individual meals is the fastest dietary lever. A randomized trial comparing low-glycemic-index diets versus standard carbohydrate advice found significantly better 1,5-AG levels in the low-GI group after three months, independent of total caloric intake. Specific tactics:

• Eat protein and non-starchy vegetables before grains and starches ("food order" strategy).
• Replace refined grains with intact whole grains to blunt the postprandial curve.
• Keep individual carbohydrate portions to 30-45 grams per meal if postprandial spikes are frequent.
• A 10-minute walk after meals reduces postprandial glucose by 30-40 mg/dL in people with insulin resistance.

GLP-1 Receptor Agonists

Semaglutide (oral or injectable), liraglutide, and tirzepatide all reduce postprandial glucose via glucose-dependent insulin secretion and delayed gastric emptying. A 26-week trial of semaglutide 1 mg weekly showed significant improvements in 1,5-AG compared to placebo in type 2 diabetes. For women with PCOS or perimenopausal insulin resistance who are not yet at the diabetes threshold, off-label use of GLP-1 agonists for postprandial control is an active area of clinical practice, though direct 1,5-AG trial data in these subgroups are limited.

Metformin

Metformin primarily targets fasting glucose and hepatic glucose output. It produces modest improvements in 1,5-AG, consistent with its secondary effect on postprandial glucose. It should not be the sole strategy when 1,5-AG is markedly low, but it remains a reasonable foundation, especially in women with PCOS where it also reduces androgen levels.

Continuous Glucose Monitoring as a Feedback Tool

Pairing a continuous glucose monitor (CGM) with serial 1,5-AG draws every four to eight weeks gives a woman real-time visibility into which meals spike her glucose and a medium-term scorecard showing whether her changes are working. This combination is the most efficient approach for optimizing the postprandial profile without waiting three months for an A1C.

Who Should Get a GlycoMark Test

This test is most informative for specific clinical situations, not as a general screening tool.

GlycoMark adds clear value when you:

• Have an A1C in the normal or prediabetes range but symptoms of postprandial dysregulation (energy crashes, reactive hypoglycemia feelings, unexplained weight gain).
• Have PCOS and your A1C does not yet qualify for diabetes but your glucose regulation feels abnormal.
• Are in perimenopause or early postmenopause and your clinician suspects accelerating insulin resistance.
• Are adjusting a medication (switching from metformin to a GLP-1 agonist, for example) and want faster feedback than A1C provides.
• Have type 1 or type 2 diabetes and your clinician wants to verify that your postprandial control is as good as your A1C implies.

GlycoMark is not appropriate when you:

• Are currently pregnant (results are physiologically suppressed and uninterpretable).
• Take an SGLT2 inhibitor (results are artifactually suppressed).
• Have an eGFR <30 mL/min/1.73m² (results trend falsely high).
• Eat a very-low-carbohydrate diet (results may trend falsely low due to reduced dietary 1,5-AG intake).

Ordering and Follow-Up Logistics

GlycoMark does not require fasting. A random blood draw is sufficient, which makes it convenient to add to any routine blood panel. The test is a send-out at most commercial labs; LabCorp and Quest both run the GlycoMark assay. Turnaround is typically two to five business days.

For monitoring treatment response, repeating 1,5-AG every four to eight weeks during a medication or diet change is reasonable, given its one-to-two-week reflection window. Once stable, including it in a quarterly or semi-annual metabolic panel alongside A1C and fasting glucose gives a complete picture of both short- and long-term glucose exposure.

The AACE/ACE Consensus Statement on glycemic monitoring recognizes that multiple biomarkers, including glycemic variability markers like 1,5-AG, are needed to fully characterize a patient's glucose control status.